Benjamin Miron, MD

Benjamin Miron, MD
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Clinical Instructor

Treatment Focus

Chemotherapy, targeted therapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies

Treatment Philosophy

I am a medical oncologist and researcher specializing in the treatment of genitourinary cancers. I became an oncologist after seeing, first hand, how impactful a caring and thoughtful physician can be for patients and their families when dealing with a cancer diagnosis. The field of oncology is rapidly evolving and my mission is to deliver the most cutting-edge, compassionate and personalized care to each and every patient. I am passionate about partnering with my patients to help them understand their disease and give them the information they need to make the best decision for them as individuals taking into account their beliefs, wishes and goals. 

I am also a scientist and the fundamental goal of my research is to improve treatment paradigms for patients with genitourinary malignancies by investigating new strategies and technologies to individualize therapy for patients to maximize benefit to them and minimize toxicity. We hope to achieve this by investigating markers that may predict a response to therapy that could be useful for selecting treatment in the future. As more drugs are being developed for genitourinary cancers it will become more important to know apriori which could be of most benefit to our patients to help us personalize their treatments. I also focus on developing and implementing tools to monitor cancers more effectively using novel technologies to detect microscopic amounts of cancer in the blood. These monitoring techniques can help us understand which patients needs to change treatment, intensify therapy or may be able to take a break from treatment all together. Collectively the goal of my research is to will hopefully help us deliver the right treatment to the right patient at the right time to help patients live longer and live better. 

Clinical Locations

Educational Background

  • New York University, New York, NY  9/2003 – 5/2007 BA 2007, Psychology (Major) Chemistry (Minor), Pre-Med
  • New York University School of Medicine, New York, NY  9/2010 – 5/2014 MD (with honors), 2014Honors Thesis: “Exploring Differential Gene Expression in Dendritic cells Induced by Regulatory T-cells.”
  • Medical Internship, Rabin Medical Center, Petach Tikvah, Israel 10/2014 – 9/2015        
  • Residency, Internal Medicine, Temple University Hospital, ABIM Physician-Scientist, Research Pathway, Philadelphia, PA 6/2017 – 6/2019
  • Temple University College of Science and Technology, Philadelphia, PA 9/2021 – 5/2022    Graduate Certificate in Bioinformatics 


  • American Board of Internal Medicine Certification, Internal Medicine        2020- Present
  • Hematology and Medical Oncology Board Eligible (2023)


  • American Society of Clinical Oncology, Member,  2016 – present
  • American Society of Hematology, Member, 2019 – present
  • American Association for Cancer Research, Member, 2020 – present 
  • European Society for Medical Oncology, Member, 2020 – present 

Honors & Awards

  • ASCO/AACR Methods in Clinical Research Workshop, Selected Participant, Vail, CO, 2022
  • Fox Chase Cancer Center, Young Investigator Award Recipient, Fox Chase Cancer Center, 2021
  • Bladder Cancer Action Network - New Discoveries Young Investigator Award Recipient, 2021
  • Sol Sherry Award for Excellence in Research - 1st Place Oral Presentations, Department of Medicine, Temple University Hospital, 2021
  • ASCO/AACR Methods in Clinical Research Workshop, Selected Participant, Vail, CO, 2020
  • Fellow of Aspen Cancer Conference, Selected Participant, Aspen, CO, 2019
  • Sol Sherry Award for Excellence in Research - 1st Place Oral Presentations, Department of Medicine, Temple University Hospital, 2019
  • Department of Medicine Resident Research Career Development Award Recipient, Department of Medicine, Temple University Hospital, 2018

Research Interests

Clinical Trials; Drug Development; Novel Therapeutics; Immunotherapy; Biomarkers; Molecular Disease Monitoring

Selected Publications

Miron B, Ritsau B, Tomaszewski JJ, Jones J, Milestone B, Wong YN, Uzzo RG, Edmondson D, Scott W, Kutikov A. Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer. Urol Case Rep. 2016;9:9-11.

Miron B, Ross E, Anari F, O’Neill J, Hoffman-Censits J, Geynisman D, Zibelman M, Kutikov A, Viterbo R, Greenberg R, Chen D, Lallas C, Trabulsi EJ, Alpaugh K, Dulaimi E, Golemis E, Uzzo R, Plimack E. Defects in DNA repair genes and long-term survival in cisplatin based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). European Urology Oncology. 2020 Aug 4; 3(4):544-547. DOI: 10.1016/j.euo.2020.02.003.

Miron B, Xu D, Zibelman M. Biomarker development for metastatic renal cell carcinoma: Omics, antigens, t-cells, and beyond. J. Pers. Med. 2020, 10, 1–18, DOI:10.3390/jpm10040225.

Miron B, Bukavina L, Plimack ER. Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer. European Urology. 2022 Jan;81(1):62-63. doi: 10.1016/j.eururo.2021.10.020. Epub 2021 Nov 5.

Laderman L, Naveed O, LoPinto-Khoury C, Dotan E, Miron B. Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma. BMJ Case Reports CP. 2022;15(5):e247676. doi:10.1136/bcr-2021-247676

Miron B, Hawley JE, Geynisman DM, et al. Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. Advances in Oncology. 2022;2(1):213-225. doi:10.1016/j.yao.2022.02.007

Miron B, Geynisman DM. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma. European Urology. Published online June 23, 2022. doi:10.1016/j.eururo.2022.05.023

Miron B, Handorf E, Zarrabi K, et al. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations. Published online July 2, 2022. doi:10.1016/j.urolonc.2022.05.028


The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...